In the Media
Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!
Visit: BioMed X and AbbVie Extend Research Collaboration in the US
BioMed X and AbbVie Extend Research Collaboration in the US
Street Insider
A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.
Visit: The BioMed X Institute: New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
The BioMed X Institute: New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
FinanzNachrichten
“We are committed to accelerating innovation across fibrotic diseases. This partnership allows us to harness top talent across the biomedical industry and leverage our leading research and development site in the U.S. to discover insights that could help transform the way we treat these diseases,” said Carine Boustany, PhD, Global Head of Immunology & Respiratory Diseases Research, Boehringer Ingelheim.
Visit: New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
Yahoo! Finance
XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, announces the start of its first research team on the Boehringer Ingelheim campus in Ridgefield, Connecticut.
Visit: New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration with Boehringer Ingelheim
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration with Boehringer Ingelheim
PharmiWeb
A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.
Visit: New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
WebDisclosure
BioMed X Institute’s new XSeed Labs research team starts activity in the U.S. in collaboration with Boehringer Ingelheim.
Visit: New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
New XSeed Labs Research Team Starts Activity in the U.S. in Collaboration With Boehringer Ingelheim
BioSpace
A new research team at XSeed Labs – a collaboration between BioMed X and Boehringer Ingelheim, will develop disease models to understand wound healing and fibrosis.
Visit: New Immuno-Oncology Research Project in Partnership With Merck KGaA Starts at the BioMed X Institute in Heidelberg
New Immuno-Oncology Research Project in Partnership With Merck KGaA Starts at the BioMed X Institute in Heidelberg
FinanzNachrichten
Dr. Semih Akincilar, the scientist leading this project, explains: “Using colorectal cancer as a model, we will investigate the molecular pathways altered in immunogenic and non-immunogenic tumor clusters. This will help us to better understand the links between DNA damage response and tumor immunogenicity, with significant implications for oncological treatment.”
Visit: New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
Yahoo! Finance
“With our most recent projects in collaboration with Merck and others, we are deepening our expertise in tumor immunology,” said Christian Tidona, Founder and Managing Director of the BioMed X Institute.
Visit: New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
New Immuno-Oncology Research Project in Partnership With Merck Starts at the BioMed X Institute in Heidelberg
BioSpace
The project is aimed at developing novel approaches to enhance tumor immunogenicity to broaden the population of patients who can benefit from cancer immunotherapy.